TABLE 3.
Antibodies against non-HLA antigens significantly altered in AMR/mixed rejection, compared, ACR and ATN
| Antibody name | Antigen specificity | Antibody levels | ||
|---|---|---|---|---|
| Before transplant | ||||
| AMR/mixed, median (IQR) | ACR, median (IQR) | P | ||
| IgG M2 | M2 (PDC-E2 + OGDC-E2 + BCOADC-E2) | 267 (0–513) | 0 (0–0) | 0.0051 |
| IgG CENP-B | Major centromere autoantigen B | 312.5 (0–877.2) | 0 (0–235.2) | 0.0097 |
| IgG Ro/SS-A (52 kDa) | Ro/SS-A (52 kDa) | 315 (0–915.7) | 0 (0–257.5) | 0.0112 |
| IgG gliadin | Gliadin | 3209 (1485.8–5474) | 1618.5 (793–3110.6) | 0.0157 |
| IgG PDH | Pyruvate dehydrogenase | 238 (0–507) | 0 (0–226) | 0.0232 |
| IgG smooth muscle | Smooth muscle actin | 382.5 (304.5–532.8) | 310.8 (230.5–374.1) | 0.0457 |
| AMR/mixed, median (IQR) | ATN, median (IQR) | P | ||
| IgM PL-12 | Alanyl-tRNA synthetase | 1049.5 (544.2–1672.8) | 352 (236.5–601) | 0.0074 |
| IgM HGMEC lysate | Glomerular endothelial cells | 1393.5 (881–2234.5) | 752 (522–1131.5) | 0.0224 |
| IgM PM/Scl-100 | PM/Scl-100 | 317.5 (0–451.5) | 0 (0–0) | 0.0234 |
| IgM OGDC-E2 | M2 (OGDC) | 426 (104.8–766) | 0 (0–307.5) | 0.0298 |
| IgG HCEC cytoplasm | Cardiac endothelial cells | 380.5 (229.2–532.7) | 222 (0–294.5) | 0.0309 |
| IgM LG3 | Basement membrane-specific heparan sulfate proteoglycan core protein | 402.5 (238.3–607.8) | 0 (0–401) | 0.0365 |
| IgM LKM 1 hp | LKM 1 hp antigen of cytochrome P450 2D6 | 210.5 (0–314) | 0 (0–0) | 0.0393 |
| IgG Ro/SS-A (60 kDa, R) | Ro/SS-A (60 kDa) | 0 (0–233.5) | 296 (0–559.5) | 0.0403 |
| IgM Sm (NR, B) | Small nuclear ribonucleoprotein Sm | 311 (0–495.7) | 0 (0–299.5) | 0.0470 |
| IgG PDH | Pyruvate dehydrogenase | 238 (0–507) | 0 (0–0) | 0.0494 |
| Antibody name | Antigen specificity | Antibody levels | ||
| At diagnosis | ||||
| AMR/mixed, median (IQR) | ACR, median (IQR) | P | ||
| IgG CENP-B | Major centromere autoantigen B | 510 (0–877.8) | 0 (0–0) | 0.0126 |
| IgG Ro/SS-A (52 kDa) | Ro/SS-A (52 kDa) | 353.5 (0–1494) | 0 (0–0) | 0.0325 |
| IgM La/SS-B | La/SS-B | 735.5 (390.8–1843) | 296 (139.5–411) | 0.0261 |
| IgM CENP-B | Major centromere autoantigen B | 666.5 (313.5–1889.5) | 262 (100.2–429) | 0.0447 |
| IgM PDH | PDH | 251 (0–684.5) | 0 (0–0) | 0.0472 |
| AMR/mixed, median (IQR) | ATN, median (IQR) | P | ||
| IgG M2 | M2 (PDC-E2 + OGDC-E2 + BCOADC-E2) | 219 (0–596.5) | 0 (0–0) | 0.0313 |
| IgG human IgA | Human IgA | 750.5 (229.5–1322) | 0 (0–337.5) | 0.0495 |
Significantly altered (P < 0.05) IgG and IgM antibodies before transplant, at diagnosis, and postdiagnosis are shown.
ACR, acute cellular rejection; AMR, antibody-mediated rejection; ATN, acute tubular necrosis; B, bovine; HLA, human leukocyte antigen; hp, high purity; Ig, immunoglobulin; IQR, interquartile range; NR, nonrecombinant; R, recombinant.